2-溴-3,6-二氟苯甲酸 | 124244-65-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-溴-3,6-二氟苯甲酸
• 英文名称: 2-bromo-3,6-difluorobenzoic acid
• CAS: 124244-65-1
• 化学式: C₇H₃BrF₂O₂
• 分子量: 237.0
• InChiKey: ZLBFRHCWALNQIJ-UHFFFAOYSA-N

物化性质

• 熔点：
  111-113 °C(Solv: heptane (142-82-5))
• 沸点：
  281.8±40.0 °C(Predicted)
• 密度：
  1.872±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2-溴-3,6-二氟苯甲酸 在 盐酸 、 bis-triphenylphosphine-palladium(II) chloride 、 硫酸 、 水 、 lithium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 生成
  参考文献：
  名称：

  Discovery of Potent, Orally Bioavailable Phthalazinone Bradykinin B1 Receptor Antagonists

  摘要：

  The bradykinin B1 receptor is rapidly induced upon tissue injury and inflammation, stimulating the production of inflammatory mediators resulting in plasma extravasation, leukocyte trafficking, edema, and pain. We have previously reported on sulfonamide and sulfone-based B1 antagonists containing a privileged bicyclic amine moiety leading to potent series of 2-oxopiperazines. The suboptimal pharmacokinetics and physicochemical properties of the oxopiperazine sulfonamides led us to seek B1 antagonists with improved druglike properties. Using a pharmacophore model containing a bicyclic amine as anchor, we designed a series of amide antagonists with targeted physicochemical properties. This approach led to a novel series of potent phthalazinone B1 antagonists, where we successfully replaced a sulfonamide acceptor with a cyclic carbonyl unit. SAR studies revealed compounds with subnanomolar B1 binding affinity. These compounds demonstrate excellent cross-species PK properties with high oral bioavailability and potent activity in a rabbit biochemical challenge pharmacodynamic study.

  DOI：

  10.1021/jm200808v
• 作为产物：
  描述：

  2,5-二氟溴苯 以70%的产率得到
  参考文献：
  名称：

  BRIDGES, ALEXANDER J.;PATT, WILLIAM C.;STICKNEY, THOMAS M., J. ORG. CHEM., 55,(1990) N, C. 773-775

  摘要：

  DOI：

文献信息

• NOVEL COMPOUNDS
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20150232460A1

  公开（公告）日：2015-08-20

  The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein L, X, R a , R b , R 1 , R 2 and R 3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了公式(I)的化合物及其药用盐，其中L、X、Ra、Rb、R1、R2和R3如规范中定义，以及其制备方法、含有它们的药物组合物以及它们在治疗中的用途。
• Regioselective ortho-lithiation of chloro and bromo substituted fluoroarenes
  作者：Florence Mongin、Manfred Schlosser

  DOI：10.1016/0040-4039(96)01398-6

  日期：1996.9

  Deprotonation of fluoroarenes carrying chlorine or bromine as additional substitutents occurs always at a fluorine adjacent position if accomplished with potassium tert-butoxide activated butyllithium or lithium 2,2,6,6-tetramethylpiperidide.

  如果用叔丁醇钾活化的丁基锂或2,2,6,6-四甲基哌啶锂完成的话，带有氯或溴作为附加取代基的氟代芳烃的脱质子反应总是在氟的相邻位置发生。
• Cycloalkyl and heterocycloalkyl compounds as orexin receptor antagonists
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US09156829B2

  公开（公告）日：2015-10-13

  The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein L, X, Ra, Rb, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了公式(I)的化合物及其药学上可接受的盐，其中L、X、Ra、Rb、R1、R2和R3如规范中所定义，以及其制备过程、含有它们的药物组合物和它们在治疗方面的用途。
• 1,2-substituted cyclopentanes as orexin receptor antagonists
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US10011588B2

  公开（公告）日：2018-07-03

  The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, (I) wherein L, X, Ra, Rb, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了式 (I) 的化合物及其药学上可接受的盐，(I) 其中 L、X、Ra、Rb、R1、R2 和 R3 如说明书中所定义，还提供了制备它们的工艺、含有它们的药物组合物以及它们在治疗中的用途。
• A dramatic solvent effect during aromatic halogen-metal exchanges. Different products from lithiation of polyfluorobromobenzenes in ether and tetrahydrofuran
  作者：Alexander J. Bridges、William C. Patt、Thomas M. Stickney

  DOI：10.1021/jo00289a069

  日期：1990.1